These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18591978)

  • 1. Dabigatran etexilate.
    Eriksson BI; Smith H; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2008 Jul; 7(7):557-8. PubMed ID: 18591978
    [No Abstract]   [Full Text] [Related]  

  • 2. Dabigatran etexilate for prevention of venous thromboembolism.
    Eikelboom JE; Weitz JI
    Thromb Haemost; 2009 Jan; 101(1):2-4. PubMed ID: 19132179
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.
    Wolowacz SE; Roskell NS; Plumb JM; Caprini JA; Eriksson BI
    Thromb Haemost; 2009 Jan; 101(1):77-85. PubMed ID: 19132192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.
    Holmes M; Carroll C; Papaioannou D
    Health Technol Assess; 2009 Sep; 13 Suppl 2():55-62. PubMed ID: 19804690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.
    Ma TK; Yan BP; Lam YY
    Pharmacol Ther; 2011 Feb; 129(2):185-94. PubMed ID: 20920530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Thrombin inhibitor shows stable safety profile in the practice].
    MMW Fortschr Med; 2008 Dec; 150(51-52):38-9. PubMed ID: 19149309
    [No Abstract]   [Full Text] [Related]  

  • 7. Dabigatran versus enoxaparin after total hip replacement.
    Martins HS; Scalabrini-Neto A; Velasco IT
    Lancet; 2007 Dec; 370(9604):2002-3; author reply 2003-4. PubMed ID: 18083399
    [No Abstract]   [Full Text] [Related]  

  • 8. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement.
    Wolowacz SE; Roskell NS; Plumb JM; Clemens A; Noack H; Robinson PA; Dolan G; Brenkel IJ
    Thromb Haemost; 2010 Feb; 103(2):360-71. PubMed ID: 20024501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.
    ; Ginsberg JS; Davidson BL; Comp PC; Francis CW; Friedman RJ; Huo MH; Lieberman JR; Muntz JE; Raskob GE; Clements ML; Hantel S; Schnee JM; Caprini JA
    J Arthroplasty; 2009 Jan; 24(1):1-9. PubMed ID: 18534438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dabigatran etexilate: a possible replacement for heparinoids and vitamin K antagonists?
    Guay DR
    Hosp Pract (1995); 2011 Feb; 39(1):105-25. PubMed ID: 21441766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery.
    Wolowacz SE
    Expert Rev Pharmacoecon Outcomes Res; 2011 Feb; 11(1):9-25. PubMed ID: 21351853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulation with {blacktriangledown}dabigatran or{blacktriangledown}rivaroxaban.
    Drug Ther Bull; 2009 Oct; 47(10):116-20. PubMed ID: 19809086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty.
    Eriksson BI; Friedman RJ
    Clin Appl Thromb Hemost; 2009; 15 Suppl 1():25S-31S. PubMed ID: 19648146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dabigatran etexilate in venous thromboembolism.
    Ferrer E
    Drugs Today (Barc); 2009 Oct; 45(10):715-24. PubMed ID: 20069135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement rationale for dose regimen.
    Dahl OE
    Clin Appl Thromb Hemost; 2009; 15 Suppl 1():17S-24S. PubMed ID: 19696041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.
    Lereun C; Wells P; Diamantopoulos A; Rasul F; Lees M; Sengupta N
    J Med Econ; 2011; 14(2):238-44. PubMed ID: 21385145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Budget impact analysis of Pradaxa thromboprophylaxis after total hip or total knee replacement].
    Bouée S; Zufferey P; Fagnani F
    Therapie; 2009; 64(4):249-57. PubMed ID: 19804705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dabigatran: new drug. Continue to use heparin, a better-known option.
    Prescrire Int; 2009 Jun; 18(101):97-9. PubMed ID: 19637411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescribing trends for dabigatran etexilate in primary care.
    McCullagh L; Barry M
    Ir Med J; 2012 May; 105(5):134-6. PubMed ID: 22803489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new approach with anticoagulant development: tailoring anticoagulant therapy with dabigatran etexilate according to patient risk.
    Rosencher N; Albaladejo P
    Expert Opin Pharmacother; 2012 Feb; 13(2):217-26. PubMed ID: 22192174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.